Focusing on Inflammation and Immune Modification to Treat PH

All credits to Prof. Paul Hassoun FPVRI, Paul Hassoun, Professor of Medicine, Director, Pulmonary Hypertension Program at Johns Hopkins University, Baltimore- MD | United States

Presented at the 1st Annual Drug Discovery and Development Symposium, July 14-15th 2014, Bethesda, USA

Additional key-words: inflammation,immune system,autoimmunity,endothelium,

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Related Content

{{GlobalController.truncateTitle("Clinical Evidence of Inflammation in PAH: A Case Study of Profibrotic Macrophages - Dr. Jane A. Leopold", 65)}}

{{GlobalController.truncateTitle("Role of Mesenchymal Cell-Macrophage Interactions in the Development of Pulmonary Vascular Remodeling and Hypertension - Dr. Kurt R. Stenmark", 65)}}

{{GlobalController.truncateTitle("An atypical presentation of adult-onset Still’s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature", 65)}}

{{GlobalController.truncateTitle("Animal models of pulmonary hypertension are consistently characterized by adventitial/peri-vascular accumulation of leukocytes, and in particular mononuclear cells", 65)}}

{{GlobalController.truncateTitle("Tuning Nrf2 stress response to enhance host defense in COPD", 65)}}

Add to reading list

Share this content

Our research platform is the world.